5-Azacytidine in Chronic Myelomonocytic Leukemia: Case Report and Review of Literature
Author Information
Author(s): Greco M., Criscuolo M., Fianchi L., Fabiani E., Pagano L., Voso MT.
Primary Institution: Istituto di Ematologia, Università Cattolica Sacro Cuore, Rome, Italy
Hypothesis
Hypomethylating drugs are useful in the management of Myelodysplastic syndromes, but there are only few reports on chronic myelomonocytic leukemia patients.
Conclusion
The study found that 5-azacytidine can lead to partial responses in some patients with chronic myelomonocytic leukemia.
Supporting Evidence
- Two patients obtained partial response after 4 treatment cycles with only minor toxicity.
- Patients were treated with 5-azacitidine at 75 mg/mq for 7 days.
- One patient progressed to acute myeloid leukemia after treatment.
Takeaway
This study shows that a medicine called 5-azacytidine can help some people with a type of blood cancer called chronic myelomonocytic leukemia feel better.
Methodology
Three patients with chronic myelomonocytic leukemia were treated with 5-azacitidine and monitored for responses and side effects.
Limitations
The study involved a small number of patients and lacked a control group.
Participant Demographics
2 men and 1 woman, median age 63 years (range 54–69).
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website